Novartis operates in more than 30 production sites worldwide. With the spin-off of our Sandoz generics and biosimilars business, our sites are now fully focused on producing innovative medicines across our priority technology platforms. Overall, we manufactured approximately 19.8 billion treatments in 2023, ensuring a continuous and reliable supply of our medicines to patients.
Contract manufacturing
At Novartis, we partner with highly-regarded pharmaceutical and biotech companies globally as a contract development and manufacturing (CDMO) partner, bringing medical innovation to life together.
Careers in Manufacturing and Supply
Learn more about careers in manufacturing, supply and quality, explore opportunities and apply for open positions.
Transforming manufacturing
The Novartis in Society Integrated Report 2023 describes how our manufacturing operations are evolving as we embrace operational excellence.
